Gastrointestinal Metastases of an Angiosarcoma

S. Obata,J. Mizutani,K. Miura,K. Kimura,K. Maeda,Y. Fujioka,Y. Matsumoto

DOI: https://doi.org/10.1055/S-2007-1010361

1993-08-01

Endoscopy

Abstract:

What problem does this paper attempt to address?

Abstract A06: A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism

Christopher M. Heaphy,Michael C. Haffner,Alan K. Meeker

DOI: https://doi.org/10.1158/1538-7445.cec13-a06

2013-07-01

Abstract:Abstract Unlimited replicative capacity is a key hallmark of cancer that requires the abrogation of telomere attrition due to the end-replication problem. The vast majority of tumors maintain telomere lengths by expressing the enzyme telomerase; however, a subset utilizes a cancer-specific, telomerase-independent telomere maintenance mechanism, termed Alternative Lengthening of Telomeres (ALT). We recently uncovered a strong correlation between ALT and recurrent cancer-associated somatic inactivating mutations in the ATRX and DAXX genes. The ATRX and DAXX proteins form a chromatin remodeling complex with histone chaperone activity, targeting incorporation of the histone variant H3.3 to G-rich repetitive regions of the genome, including the telomeres, which are known to normally be maintained in a repressed heterochromatic state. Here, we have developed an isogenic cell line pair derived from first generation telomerase knock-out (KO) mouse embryonic fibroblasts. Compared to early-passage telomerase KO cells and late passage WT control cells, late-passage telomerase KO cells spontaneously developed the ALT phenotype. These ALT(+) cells display increased DNA damage, as observed by dramatically increased accumulation of γH2AX foci. We plan to use this unique cell line to identify drugs exhibiting selective toxicity for ALT(+) cells. Preliminary results indicate that ALT(+) late-passage telomerase KO cells exhibit an increased sensitivity to the DNA-PK inhibitor NU7441 compared to the isogenic early-passage ALT(-) telomerase KO cells. The identification of bona fide ALT-specific drugs will pave the way for the development of new targeted treatments for the significant number of cancers that harbor this unique molecular phenotype. Citation Format: Christopher M. Heaphy, Michael C. Haffner, Alan K. Meeker. A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Jun 19-22, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2013;73(13 Suppl):Abstract nr A06.
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

Courtney A. Lovejoy,Wendi Li,Steven Reisenweber,Supawat Thongthip,Joanne Bruno,Titia de Lange,Saurav De,John H. J. Petrini,Patricia A. Sung,Maria Jasin,Joseph Rosenbluh,Yaara Zwang,Barbara A. Weir,Charlie Hatton,Elena Ivanova,Laura Macconaill,Megan Hanna,William C. Hahn,Neal F. Lue,Roger R. Reddel,Yuchen Jiao,Kenneth Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Alan K. Meeker,,

DOI: https://doi.org/10.1371/journal.pgen.1002772

IF: 4.5

2012-07-19

PLoS Genetics

Abstract:The Alternative Lengthening of Telomeres (ALT) pathway is a telomerase-independent pathway for telomere maintenance that is active in a significant subset of human cancers and in vitro immortalized cell lines. ALT is thought to involve templated extension of telomeres through homologous recombination, but the genetic or epigenetic changes that unleash ALT are not known. Recently, mutations in the ATRX/DAXX chromatin remodeling complex and histone H3.3 were found to correlate with features of ALT in pancreatic neuroendocrine cancers, pediatric glioblastomas, and other tumors of the central nervous system, suggesting that these mutations might contribute to the activation of the ALT pathway in these cancers. We have taken a comprehensive approach to deciphering ALT by applying genomic, molecular biological, and cell biological approaches to a panel of 22 ALT cell lines, including cell lines derived in vitro. Here we show that loss of ATRX protein and mutations in the ATRX gene are hallmarks of ALT-immortalized cell lines. In addition, ALT is associated with extensive genome rearrangements, marked micronucleation, defects in the G2/M checkpoint, and altered double-strand break (DSB) repair. These attributes will facilitate the diagnosis and treatment of ALT positive human cancers.

genetics & heredity
Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks

Jia-Min Zhang,Lee Zou

DOI: https://doi.org/10.1186/s13578-020-00391-6

2020-03-10

Abstract:Abstract To escape replicative senescence, cancer cells have to overcome telomere attrition during DNA replication. Most of cancers rely on telomerase to extend and maintain telomeres, but 4–11% of cancers use a homologous recombination-based pathway called alternative lengthening of telomeres (ALT). ALT is prevalent in cancers from the mesenchymal origin and usually associates with poor clinical outcome. Given its critical role in protecting telomeres and genomic integrity in tumor cells, ALT is an Achilles heel of tumors and an attractive target for cancer therapy. Here, we review the recent progress in the mechanistic studies of ALT, and discuss the emerging therapeutic strategies to target ALT-positive cancers.

biochemistry & molecular biology
Abstract B14: Establishment and characterization of in vitro models of alternative lengthening of telomeres (ALT) in pediatric high-grade glioma

Jacqueline A. Brosnan-Cashman,Mindy K. Graham,Anthony J. Rizzo,Kaylar Myers,Rebecca Zhang,Ezgi Göger,Reza Zarinshenas,Christine Davis,Ming Yuan,Dinesh Rakheja,Eric H. Raabe,Charles G. Eberhart,Christopher M. Heaphy,Alan K. Meeker

DOI: https://doi.org/10.1158/1538-7445.pedca17-b14

2018-10-01

Abstract:Abstract Telomeres consist of many kilobases of repeated TTAGGG sequences at the ends of chromosomes, protected by a sequence-specific protein cap. Telomeres progressively shorten with each cell division and ultimately become critically short; due to their extensive proliferation, cancer cells must find a way to counteract this telomere loss. While most cancers utilize telomerase to maintain their telomere length, about 5% of cancers use a telomerase-independent telomere maintenance strategy, termed alternative lengthening of telomeres (ALT). While, overall, ALT is rare in cancer (~5-10% of cases), this telomere maintenance mechanism is enriched in pediatric high-grade glioma (pHGG). Previous work in our laboratory suggests that nearly half of pHGG utilize ALT. To date, therapeutic options are largely ineffective for children with HGG, reflected in the five-year survival rate, which is less than 33%. Our goal is to better harness ALT as a clinical marker in pHGG, specifically by the identification of drugs that target ALT-positive cancers. In order to study ALT in this context, we obtained and characterized a panel of six pHGG cell lines. Two of these six pHGG cell lines displayed features of ALT, including the presence of ALT-associated PML bodies and extrachromosomal telomeric DNA in the form of c-circles. Furthermore, these lines lacked measurable telomerase activity. It is well established that ATRX is commonly mutated in ALT-positive cancers, including pHGG. Interestingly, only one of these two ALT-positive pHGG cell lines displayed total loss of ATRX; the second cell line has an in-frame deletion in the ATRX gene, which may provide insight into the mechanism of how ATRX acts to suppress ALT. In addition, we have generated ATRX knockout cell lines from the four ALT-negative pHGG cells identified in this panel. Despite the strong link between ATRX loss and ALT in clinical samples, only one cell line displayed ALT characteristics after ATRX knockout. Comparison of the ALT-competent cell line to the ALT-resistant cell lines will yield important information about additional genetic or epigenetic events that allow ALT to occur. In conclusion, we have established in vitro models of ALT in pHGG cell lines based on endogenous ALT positivity and induction of ALT-like features based on ATRX modulation. These models will be invaluable resources as we strive to understand the molecular characteristics of ALT and translate these findings to better therapies for children with pHGG. Citation Format: Jacqueline A. Brosnan-Cashman, Mindy K. Graham, Anthony J. Rizzo, Kaylar Myers, Rebecca Zhang, Ezgi Göger, Reza Zarinshenas, Christine Davis, Ming Yuan, Dinesh Rakheja, Eric H. Raabe, Charles G. Eberhart, Christopher M. Heaphy, Alan K. Meeker. Establishment and characterization of in vitro models of alternative lengthening of telomeres (ALT) in pediatric high-grade glioma [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr B14.
Alternative Lengthening of Telomeres and Mediated Telomere Synthesis

Kailong Hou,Yuyang Yu,Duda Li,Yanduo Zhang,Ke Zhang,Jinkai Tong,Kunxian Yang,Shuting Jia

DOI: https://doi.org/10.3390/cancers14092194

2022-04-27

Cancers

Abstract:Telomeres are DNA–protein complexes that protect eukaryotic chromosome ends from being erroneously repaired by the DNA damage repair system, and the length of telomeres indicates the replicative potential of the cell. Telomeres shorten during each division of the cell, resulting in telomeric damage and replicative senescence. Tumor cells tend to ensure cell proliferation potential and genomic stability by activating telomere maintenance mechanisms (TMMs) for telomere lengthening. The alternative lengthening of telomeres (ALT) pathway is the most frequently activated TMM in tumors of mesenchymal and neuroepithelial origin, and ALT also frequently occurs during experimental cellular immortalization of mesenchymal cells. ALT is a process that relies on homologous recombination (HR) to elongate telomeres. However, some processes in the ALT mechanism remain poorly understood. Here, we review the most recent understanding of ALT mechanisms and processes, which may help us to better understand how the ALT pathway is activated in cancer cells and determine the potential therapeutic targets in ALT pathway-stabilized tumors.

oncology
Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants

Jennifer L Stundon,Heba Ijaz,Krutika S Gaonkar,Rebecca S Kaufman,Run Jin,Anastasios Karras,Zalman Vaksman,Jung Kim,Ryan J Corbett,Matthew R Lueder,Daniel P Miller,Yiran Guo,Mariarita Santi,Marilyn Li,Gonzalo Lopez,Phillip B Storm,Adam C Resnick,Angela J Waanders,Suzanne P MacFarland,Douglas R Stewart,Sharon J Diskin,Jo Lynne Rokita,Kristina A Cole

DOI: https://doi.org/10.1093/neuonc/noac278

2023-07-06

Abstract:Background: To achieve replicative immortality, most cancers develop a telomere maintenance mechanism, such as reactivation of telomerase or alternative lengthening of telomeres (ALT). There are limited data on the prevalence and clinical significance of ALT in pediatric brain tumors, and ALT-directed therapy is not available. Methods: We performed C-circle analysis (CCA) on 579 pediatric brain tumors that had corresponding tumor/normal whole genome sequencing through the Open Pediatric Brain Tumor Atlas (OpenPBTA). We detected ALT in 6.9% (n = 40/579) of these tumors and completed additional validation by ultrabright telomeric foci in situ on a subset of these tumors. We used CCA to validate TelomereHunter for computational prediction of ALT status and focus subsequent analyses on pediatric high-grade gliomas (pHGGs) Finally, we examined whether ALT is associated with recurrent somatic or germline alterations. Results: ALT is common in pHGGs (n = 24/63, 38.1%), but occurs infrequently in other pediatric brain tumors (<3%). Somatic ATRX mutations occur in 50% of ALT+ pHGGs and in 30% of ALT- pHGGs. Rare pathogenic germline variants in mismatch repair (MMR) genes are significantly associated with an increased occurrence of ALT. Conclusions: We demonstrate that ATRX is mutated in only a subset of ALT+ pHGGs, suggesting other mechanisms of ATRX loss of function or alterations in other genes may be associated with the development of ALT in these patients. We show that germline variants in MMR are associated with the development of ALT in patients with pHGG.
A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway

Merrill M Froney,Christian R Cook,Alyssa M Cadiz,Katherine A Flinter,Sara T Ledeboer,Bianca Chan,Lauren E Burris,Brian P Hardy,Kenneth H Pearce,Alexis C Wardell,Brian T Golitz,Michael B Jarstfer,Samantha G Pattenden

DOI: https://doi.org/10.1021/acsptsci.4c00251

2024-08-13

Abstract:Telomeres are a protective cap that prevents chromosome ends from being recognized as double-stranded breaks. In somatic cells, telomeres shorten with each cell division due to the end replication problem, which eventually leads to senescence, a checkpoint proposed to prevent uncontrolled cell growth. Tumor cells avoid telomere shortening by activating one of two telomere maintenance mechanisms (TMMs): telomerase reactivation or alternative lengthening of telomeres (ALT). TMMs are a viable target for cancer treatment as they are not active in normal, differentiated cells. Whereas there is a telomerase inhibitor currently undergoing clinical trials, there are no known ALT inhibitors in development, partially because the complex ALT pathway is still poorly understood. For cancers such as neuroblastoma and osteosarcoma, the ALT-positive status is associated with an aggressive phenotype and few therapeutic options. Thus, methods that characterize the key biological pathways driving ALT will provide important mechanistic insight. We have developed a first-in-class phenotypic high-throughput screen to identify small-molecule inhibitors of ALT. Our screen measures relative C-circle level, an ALT-specific biomarker, to detect changes in ALT activity induced by compound treatment. To investigate epigenetic mechanisms that contribute to ALT, we screened osteosarcoma and neuroblastoma cells against an epigenetic-targeted compound library. Hits included compounds that target chromatin-regulating proteins and DNA damage repair pathways. Overall, the high-throughput C-circle assay will help expand the repertoire of potential ALT-specific therapeutic targets and increase our understanding of ALT biology.
Alternative lengthening of telomeres: models, mechanisms and implications

Anthony J. Cesare,Roger R. Reddel

DOI: https://doi.org/10.1038/nrg2763

IF: 59.581

2010-03-30

Nature Reviews Genetics

Abstract:Key PointsAbout 10% of all cancers, including some that have a particularly poor prognosis, use the alternative lengthening of telomeres (ALT) pathway to prevent the telomere shortening that accompanies proliferation of normal cells.ALT-positive cells commonly have a number of unusual characteristics, including telomeric DNA that is separated from chromosome ends. This extrachromosomal telomeric DNA may be linear or circular.Partially single-stranded circles of telomeric DNA in which the C-rich (AATCCC)n strand is essentially intact and the G-rich (TTAGGG)n strand is gapped seem to be the best of the known markers for ALT. The quantity of this 'C-circle' DNA correlates well with the amount of ALT activity.Telomere elongation in ALT cells involves homologous recombination.The experimental evidence fits best with a model for ALT in which telomeric 3′ overhangs become extended by invading other telomeric DNA and using it as a template for DNA replication. The other telomeric DNA can be: part of the same telomere (through telomere-loop formation); in a sister chromatid; in the telomere of another chromosome; or in one of the forms of extrachromosomal telomeric DNA.Proteins that are thought to be required for ALT include the homologous recombination protein complexes MRN (which is made up of meiotic recombination 11 (MRE11, also known as MRE11A), RAD50 and Nijmegen breakage syndrome 1 (NBS1, also known as NBN)) and structural maintenance of chromosomes 5 (SMC5)–SMC6, and proteins, such as flap endonuclease 1 (FEN1), MUS81, Fanconi anaemia group D2 (FANCD2) and Fanconi anaemia group A (FANCA), that may be required for recombination-dependent restart of stalled telomeric DNA replication.Promyelocytic leukaemia (PML) bodies containing telomeric DNA are characteristic of ALT cells, and are referred to as ALT-associated PML bodies (APBs). Large APBs seem to be associated with senescence of ALT cells and sequestration of extrachromosomal DNA, but we speculate that smaller APBs may be sites at which telomere lengthening occurs.In ALT cells, many of the telomeres elicit a DNA-damage response but repress chromosome end-to-end fusions. This telomere state, which is intermediate between the fully capped and uncapped fusogenic telomere states, may reflect a structural change that is permissive for recombination-mediated telomere replication.

genetics & heredity
Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

Mindy K Graham,Jiyoung Kim,Joseph Da,Jacqueline A Brosnan-Cashman,Anthony Rizzo,Javier A Baena Del Valle,Lionel Chia,Michael Rubenstein,Christine Davis,Qizhi Zheng,Leslie Cope,Michael Considine,Michael C Haffner,Angelo M De Marzo,Alan K Meeker,Christopher M Heaphy

DOI: https://doi.org/10.1158/1541-7786.MCR-19-0654

Abstract:A key hallmark of cancer, unlimited replication, requires cancer cells to evade both replicative senescence and potentially lethal chromosomal instability induced by telomere dysfunction. The majority of cancers overcome these critical barriers by upregulating telomerase, a telomere-specific reverse transcriptase. However, a subset of cancers maintains telomere lengths by the telomerase-independent Alternative Lengthening of Telomeres (ALT) pathway. The presence of ALT is strongly associated with recurrent cancer-specific somatic inactivating mutations in the ATRX-DAXX chromatin-remodeling complex. Here, we generate an ALT-positive adenocarcinoma cell line following functional inactivation of ATRX and telomerase in a telomerase-positive adenocarcinoma cell line. Inactivating mutations in ATRX were introduced using CRISPR-cas9 nickase into two prostate cancer cell lines, LAPC-4 (derived from a lymph node metastasis) and CWR22Rv1 (sourced from a xenograft established from a primary prostate cancer). In LAPC-4, but not CWR22Rv1, abolishing ATRX was sufficient to induce multiple ALT-associated hallmarks, including the presence of ALT-associated promyelocytic leukemia bodies (APB), extrachromosomal telomere C-circles, and dramatic telomere length heterogeneity. However, telomerase activity was still present in these ATRXKO cells. Telomerase activity was subsequently crippled in these LAPC-4 ATRXKO cells by introducing mutations in the TERC locus, the essential RNA component of telomerase. These LAPC-4 ATRXKO TERCmut cells continued to proliferate long-term and retained ALT-associated hallmarks, thereby demonstrating their reliance on the ALT mechanism for telomere maintenance. IMPLICATIONS: These prostate cancer cell line models provide a unique system to explore the distinct molecular alterations that occur upon induction of ALT, and may be useful tools to screen for ALT-specific therapies.
Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

Rita T Lawlor,Nicola Veronese,Antonio Pea,Alessia Nottegar,Lee Smith,Camilla Pilati,Jacopo Demurtas,Matteo Fassan,Liang Cheng,Claudio Luchini

DOI: https://doi.org/10.1186/s12885-019-5424-8

IF: 4.638

2019-03-14

BMC Cancer

Abstract:Background: Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods: We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- patients as the primary outcome. The secondary outcome was the hazard ratio (HR), adjusted for the maximum number of covariates available, using ALT- patients as reference. Results: Eight articles comprising a total of 551 patients with sarcomas (226 ALT+ and 325 ALT-) were selected. The ALT+ group showed a higher mitotic count and a higher tumor grade compared with the ALT- group (p < 0.01). Furthermore, we demonstrate a strong impact of ALT on survival. In fact, ALT+ patients showed a statistically significant higher risk of death than ALT- patients, when also considering data from multivariate analyses (RR = 1.50; 95% CI: 1.15-1.96; p = 0.003; HR = 2.02; 95% CI: 1.22-3.38; p = 0.007). Conclusions: Our results indicate that ALT is associated with an increased risk of death in patients with sarcoma. In these neoplasms, ALT should be taken into account for a precise prognostic stratification and design of potential therapeutic strategies.
Alternative Lengthening of Telomeres: DNA Repair Pathways Converge

Alexander P. Sobinoff,Hilda A. Pickett

DOI: https://doi.org/10.1016/j.tig.2017.09.003

IF: 11.4

2017-12-01

Trends in Genetics

Abstract:Telomeres shorten during each cellular division, with cumulative attrition resulting in telomeric damage and replicative senescence. Bypass of replicative senescence precipitates catastrophic telomere shortening or crisis, and is characterized by widespread genomic instability. Activation of a telomere maintenance mechanism (TMM) is necessary to stabilise the genome and establish cellular immortality through the reconstitution of telomere capping function. The alternative lengthening of telomeres (ALT) pathway is a TMM frequently activated in tumors of mesenchymal or neuroepithelial origin. ALT is a homology-directed recombination-dependent replication pathway that utilizes telomeric templates for synthesis; however, its precise protein requirements have remained elusive. Recently, several developments have shed light on the DNA repair pathways that become engaged at ALT telomeres, implicating ALT telomeres as DNA repair hot spots. Here, we review recent discoveries regarding the ALT mechanism, and discuss how DNA repair pathways converge to maintain the length and functional integrity of telomeres in ALT cancers.

genetics & heredity
Orphan nuclear receptors promote alternative lengthening of telomeres (ALT) through ALT-associated PML bodies

Venus Marie Gaela,Hsuan-Yu Hsia,Thomas Boudier,Liuh-Yow Chen

DOI: https://doi.org/10.1101/2022.03.30.485724

2022-03-30

Abstract:ABSTRACT Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere maintenance mechanism utilized by about 15% of cancers. Orphan nuclear receptors (NRs), such as COUP-TF1, COUP-TF2, EAR2, TR2, and TR4, associate with telomeres of ALT cells by binding to variant telomeric repeats. However, how these orphan NRs function in the ALT pathway remains to be characterized. Here, we have established an ALT-inducing cell model by tethering orphan NRs to telomeres in non-ALT BJ fibroblast cells. We demonstrate that recruitment of orphan NRs to telomeres is sufficient to initiate formation of ALT-associated promyelocytic leukemia nuclear bodies (APBs) and telomeric DNA synthesis at APBs. We found that the ability of orphan NRs to initiate APB formation and recombination is dependent on the orphan NR AF2 domain, the zinc-finger protein ZNF827, and PML protein. Depletion of orphan NRs in ALT cell lines reduced APB formation and telomeric DNA synthesis, confirming the role of orphan NRs in ALT cells. Furthermore, we found that ATRX/DAXX depletion, together with the telomeric localization of orphan NRs, induces APB formation, telomere clustering, and telomeric DNA synthesis more dramatically in non-ALT cells. Accordingly, we propose that these events in ALT, orphan NR recruitment to telomeres and ATRX/DAXX loss, operate in concert to activate the ALT pathway.
Abstract LT07: Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)

Frances Kusuma,Aishvaryaa Prabhu,Galen Tieo,Syed Moiz Ahmad,Pushkar Dakle,Wai Khang Yong,Elina Pathak,Vikas Madan,Yan Yi Jiang,Wai Leong Tam,Dennis Kappei,Peter Dröge,H. Phillip Koeffler,Maya Jeitany

DOI: https://doi.org/10.1158/1538-7445.fcs2023-lt07

IF: 11.2

2024-04-16

Cancer Research

Abstract:Enabling replicative immortality is one prominent feature of cancer cells. To that end, cancer cells activate means to elongate their telomeres. While 85% of cancers re-express telomerase, around 15% of all cancers rely on the ALT (Alternative Lengthening of Telomeres) mechanism. Despite its frequency, no clinically approved ALT-targeted therapy exists to date. By performing anti-cancer compound library screen on isogenic cell lines and using extrachromosomal telomeric C-circles, as a bona fide marker of ALT activity, we identified a receptor tyrosine kinase inhibitor, ponatinib, that deregulates ALT mechanisms, induces telomeric dysfunction, reduced ALT- associated telomere synthesis, and targets, in vivo, ALT-positive cells. By scrutinizing the mode of action of ponatinib on ALT, we identified an ABL1-JNK-JUN signalling circuit to be inhibited by ponatinib and to have a role in suppressing extrachromosomal telomeric C-circle formation. Furthermore, transcriptome and interactome analyses of JUN suggested a role of JUN in DNA damage repair pathways, independently of its capacity as a transcription factor. These results were corroborated by new synergistic drug interactions between ponatinib and either DNA synthesis or repair inhibitors such as triciribine and KU-60019, respectively. Overall, we identified a novel signalling pathway impacting ALT which can be targeted by a clinically approved kinase inhibitor. Citation Format: Frances Kusuma, Aishvaryaa Prabhu, Galen Tieo, Syed Moiz Ahmad, Pushkar Dakle, Wai Khang Yong, Elina Pathak, Vikas Madan, Yan Yi Jiang, Wai Leong Tam, Dennis Kappei, Peter Dröge, H. Phillip Koeffler, Maya Jeitany. Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT) [abstract]. In: Proceedings of Frontiers in Cancer Science; 2023 Nov 6-8; Singapore. Philadelphia (PA): AACR; Cancer Res 2024;84(8_Suppl) nr LT07.

oncology
Orphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibition

Venus Marie Gaela,Hsuan-Yu Hsia,Nithila A Joseph,Wan-Yi Tzeng,Pin-Chao Ting,Yi-Ling Shen,Chia-Tsen Tsai,Thomas Boudier,Liuh-Yow Chen

DOI: https://doi.org/10.1093/nar/gkae389

IF: 14.9

2024-05-17

Nucleic Acids Research

Abstract:Orphan nuclear receptors (NRs), such as COUP-TF1, COUP-TF2, EAR2, TR2 and TR4, are implicated in telomerase-negative cancers that maintain their telomeres through the alternative lengthening of telomeres (ALT) mechanism. However, how telomere association of orphan NRs is involved in ALT activation remains unclear. Here, we demonstrate that telomeric tethering of orphan NRs in human fibroblasts initiates formation of ALT-associated PML bodies (APBs) and features of ALT activity, including ALT telomere DNA synthesis, telomere sister chromatid exchange, and telomeric C-circle generation, suggesting de novo ALT induction. Overexpression of orphan NRs exacerbates ALT phenotypes in ALT cells, while their depletion limits ALT. Orphan NRs initiate ALT via the zinc finger protein 827, suggesting the involvement of chromatin structure alterations for ALT activation. Furthermore, we found that orphan NRs and deficiency of the ALT suppressor ATRX-DAXX complex operate in concert to promote ALT activation. Moreover, PML depletion by gene knockout or arsenic trioxide treatment inhibited ALT induction in fibroblasts and ALT cancer cells, suggesting that APB formation underlies the orphan NR-induced ALT activation. Importantly, arsenic trioxide administration abolished APB formation and features of ALT activity in ALT cancer cell line-derived mouse xenografts, suggesting its potential for further therapeutic development to treat ALT cancers.

biochemistry & molecular biology
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner

Jacqueline A. Brosnan-Cashman,Ming Yuan,Mindy K. Graham,Anthony J. Rizzo,Kaylar M. Myers,Christine Davis,Rebecca Zhang,David M. Esopi,Eric H. Raabe,Charles G. Eberhart,Christopher M. Heaphy,Alan K. Meeker

DOI: https://doi.org/10.1371/journal.pone.0204159

IF: 3.7

2018-09-18

PLoS ONE

Abstract:Cancers must maintain their telomeres at lengths sufficient for cell survival. In several cancer subtypes, a recombination-like mechanism termed alternative lengthening of telomeres (ALT), is frequently used for telomere length maintenance. Cancers utilizing ALT often have lost functional ATRX, a chromatin remodeling protein, through mutation or deletion, thereby strongly implicating ATRX as an ALT suppressor. Herein, we have generated functional ATRX knockouts in four telomerase-positive, ALT-negative human glioma cell lines: MOG-G-UVW, SF188, U-251 and UW479. After loss of ATRX, two of the four cell lines (U-251 and UW479) show multiple characteristics of ALT-positive cells, including ultrabright telomeric DNA foci, ALT-associated PML bodies, and c-circles. However, telomerase activity and overall telomere length heterogeneity are unaffected after ATRX loss, regardless of cellular context. The two cell lines that showed ALT hallmarks after complete ATRX loss also did so upon ATRX depletion via shRNA-mediated knockdown. These results suggest that other genomic or epigenetic events, in addition to ATRX loss, are necessary for the induction of ALT in human cancer.

multidisciplinary sciences
Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)

Marco De Vitis,Francesco Berardinelli,Antonella Sgura

DOI: https://doi.org/10.3390/ijms19020606

IF: 5.6

2018-02-18

International Journal of Molecular Sciences

Abstract:Eukaryotic cells undergo continuous telomere shortening as a consequence of multiple rounds of replications. During tumorigenesis, cells have to acquire telomere DNA maintenance mechanisms (TMMs) in order to counteract telomere shortening, to preserve telomeres from DNA damage repair systems and to avoid telomere-mediated senescence and/or apoptosis. For this reason, telomere maintenance is an essential step in cancer progression. Most human tumors maintain their telomeres expressing telomerase, whereas a lower but significant proportion activates the alternative lengthening of telomeres (ALT) pathway. However, evidence about the coexistence of ALT and telomerase has been found both in vivo in the same cancer populations and in vitro in engineered cellular models, making the distinction between telomerase- and ALT-positive tumors elusive. Indeed, after the development of drugs able to target telomerase, the capability for some cancer cells to escape death, switching from telomerase to ALT, was highlighted. Unfortunately, to date, the mechanism underlying the possible switching or the coexistence of telomerase and ALT within the same cell or populations is not completely understood and different factors could be involved. In recent years, different studies have tried to shed light on the complex regulation network that controls the transition between the two TMMs, suggesting a role for embryonic cancer origin, epigenetic modifications, and specific genes activation-both in vivo and in vitro. In this review, we examine recent findings about the cancer-associated differential activation of the two known TMMs and the possible factors implicated in this process. Furthermore, some studies on cancers are also described that did not display any TMM.

biochemistry & molecular biology,chemistry, multidisciplinary
RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres

Jonathan Barroso-González,Laura García-Expósito,Song My Hoang,Michelle L Lynskey,Justin L Roncaioli,Arundhati Ghosh,Callen T Wallace,Marco de Vitis,Mauro Modesti,Kara A Bernstein,Saumendra N Sarkar,Simon C Watkins,Roderick J O'Sullivan

DOI: https://doi.org/10.1016/j.molcel.2019.06.043

2019-10-03

Abstract:Alternative lengthening of telomeres (ALT) is a homology-directed repair (HDR) mechanism of telomere elongation that controls proliferation in aggressive cancers. We show that the disruption of RAD51-associated protein 1 (RAD51AP1) in ALT+ cancer cells leads to generational telomere shortening. This is due to RAD51AP1's involvement in RAD51-dependent homologous recombination (HR) and RAD52-POLD3-dependent break induced DNA synthesis. RAD51AP1 KO ALT+ cells exhibit telomere dysfunction and cytosolic telomeric DNA fragments that are sensed by cGAS. Intriguingly, they activate ULK1-ATG7-dependent autophagy as a survival mechanism to mitigate DNA damage and apoptosis. Importantly, RAD51AP1 protein levels are elevated in ALT+ cells due to MMS21 associated SUMOylation. Mutation of a single SUMO-targeted lysine residue perturbs telomere dynamics. These findings indicate that RAD51AP1 is an essential mediator of the ALT mechanism and is co-opted by post-translational mechanisms to maintain telomere length and ensure proliferation of ALT+ cancer cells.
Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes

Jaewon Min,Woodring E. Wright,Jerry W. Shay

DOI: https://doi.org/10.1128/mcb.00226-17

IF: 5.069

2017-10-15

Molecular and Cellular Biology

Abstract:ABSTRACT Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere maintenance mechanism that occurs in a subset of cancers. By analyzing telomerase-positive cells and their human TERC knockout-derived ALT human cell lines, we show that ALT cells harbor more fragile telomeres representing telomere replication problems. ALT-associated replication defects trigger mitotic DNA synthesis (MiDAS) at telomeres in a RAD52-dependent, but RAD51-independent, manner. Telomeric MiDAS is a conservative DNA synthesis process, potentially mediated by break-induced replication, similar to type II ALT survivors in Saccharomyces cerevisiae . Replication stresses induced by ectopic oncogenic expression of cyclin E, G-quadruplexes, or R-loop formation facilitate the ALT pathway and lead to telomere clustering, a hallmark of ALT cancers. The TIMELESS/TIPIN complex suppresses telomere clustering and telomeric MiDAS, whereas the SMC5/6 complex promotes them. In summary, ALT cells exhibit more telomere replication defects that result in persistent DNA damage responses at telomeres, leading to the engagement of telomeric MiDAS (spontaneous mitotic telomere synthesis) that is triggered by DNA replication stress, a potential driver of genomic duplications in cancer.

cell biology,biochemistry & molecular biology

Gastrointestinal Metastases of an Angiosarcoma

Abstract A06: A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks

Abstract B14: Establishment and characterization of in vitro models of alternative lengthening of telomeres (ALT) in pediatric high-grade glioma

Alternative Lengthening of Telomeres and Mediated Telomere Synthesis

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants

A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway

Alternative lengthening of telomeres: models, mechanisms and implications

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

Alternative Lengthening of Telomeres: DNA Repair Pathways Converge

Orphan nuclear receptors promote alternative lengthening of telomeres (ALT) through ALT-associated PML bodies

Abstract LT07: Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)

Orphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibition

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)

RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres

Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes